- An enzyme called heme oxygenase-1 (HO-1) affects immune cells as they travel through the body in response to kidney injury.
- In mice, the absence of HO-1 leads to poor recovery after acute kidney injury.
Washington, DC (February 12, 2015) -- An enzyme known to be important in the body's response to kidney injury exerts its protective effects, in part, by affecting the immune system, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings could lead to new treatments for patients with acute kidney injury (AKI).
AKI is an abrupt decline in kidney function that often arises after major surgeries or severe infections. An enzyme called heme oxygenase-1 (HO-1) is known to be important in the body's protective response to AKI. In their efforts to uncover the specific effects of HO-1 in this response, a team of researchers led by Anupam Agarwal, MD, James F. George, PhD, Travis Hull, BS, and Ahmed Kamal, MD (University of Alabama at Birmingham) found that HO-1 helps to direct a specific subset of immune cells, called myeloid cells, as they traffic to and from the kidney after it is injured.
"This pre-clinical study more completely defines the cellular compartments through which HO-1 exerts its protective effects in AKI, thus paving the way for the development of targeted novel therapeutic strategies aimed at preventing the significant morbidity and mortality caused by AKI in patients," said Dr. Agarwal. "More importantly, our studies discovered that the absence of HO-1 in myeloid cells had a dramatic effect on recovery after AKI, suggesting that HO-1 could be an important target in preventing the transition of AKI to chronic kidney disease."
In an accompanying editorial, Gilbert Kinsey, PharmD, PhD (University of Virginia) noted that the findings significantly advance researchers' understanding of the role of HO-1 following kidney injury. "Given the human relevance of HO-1 in AKI and the growing understanding of the myeloid cells in renal health and disease, these studies by Hull et al. provide the foundation for a whole new area of AKI research," he wrote.
Study co-authors include Ravindra Boddu, PhD, DDS, Subhashini Bolisetty, PhD, Lingling Guo, MD, Cornelia Tisher, BS, Sunil Rangarajan, MD, Bo Chen, MD, and Lisa Curtis, PhD.
Disclosures: The authors reported no financial disclosures.
The article, entitled "Heme Oxygenase-1 Regulates Myeloid Cell Trafficking in AKI," will appear online at http://jasn.
The editorial, entitled "Myeloid Cell HO-ming in AKI," will appear online at http://jasn.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 15,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.